News &amp; Updates

Is docetaxel helpful in metastatic hormone-sensitive prostate cancer?

Treatment with docetaxel appears beneficial in patients with low- and high-burden metastatic hormone-sensitive prostate cancer, a study has shown. However, no consistent differences for overall survival are seen in subgroup analyses as regards volume of metastatic disease.

Is docetaxel helpful in metastatic hormone-sensitive prostate cancer?

02 Dec 2021

Nivolumab a potential treatment for metastatic thymic epithelial tumours

Nivolumab is a promising therapy for patients with thymic epithelial tumours who have received multiple-line treatments, suggests a study. However, the high rate of severe toxicities specifies a need to find out a reliable marker to predict patients who will derive benefit or exhibit toxicity.

Nivolumab a potential treatment for metastatic thymic epithelial tumours

Fimasartan noninferior to perindopril in older adults with essential hypertension

01 Dec 2021 by

In the treatment of older patients with essential hypertension, fimasartan alone or combined with hydrochlorothiazide demonstrates comparable safety and efficacy to perindopril monotherapy or in combination with indapamide, as shown in the results of a phase IIIb trial.

Fimasartan noninferior to perindopril in older adults with essential hypertension

Initiation of biosimilar pegfilgrastim helps reduce cost, financial pressure on healthcare system

The introduction of pegfilgrastim biosimilar may lower the cost and lessen some of the financial pressure on the healthcare system, suggests a study in France.

Initiation of biosimilar pegfilgrastim helps reduce cost, financial pressure on healthcare system

Folate supplementation helps increase ovarian reserve

Higher intake of folate, specifically from supplements, results in a modest increase in ovarian reserve among women, as shown in a study.

Folate supplementation helps increase ovarian reserve

Cardiorenal benefit with investigational GLP-1 RA independent of concurrent SGLT2 inhibitor

30 Nov 2021 by

The glucagon-like peptide-1 receptor agonist (GLP-1 RA) efpeglenatide affords cardiovascular and renal protection that is not explained by concurrent use of a sodium-glucose co-transporter-2 (SGLT2) inhibitor in patients with type 2 diabetes (T2D), according to an exploratory analysis of AMPLITUDE-O.

Cardiorenal benefit with investigational GLP-1 RA independent of concurrent SGLT2 inhibitor

30 Nov 2021

New chest pain guideline: Takeaways & Concerns

30 Nov 2021 by

A new guideline on chest pain evaluation and diagnosis – touted as the first of its kind – is now out, reaping both praises and dissent from experts.

New chest pain guideline: Takeaways & Concerns

Phase II data underscores lanifibranor potential for NASH

30 Nov 2021 by

In the phase IIb NATIVE* trial, the pan-PPAR** agonist lanifibranor demonstrated histologic benefits for patients with nonalcoholic steatohepatitis (NASH).

Phase II data underscores lanifibranor potential for NASH

What is the optimal tanezumab dose, administration route for osteoarthritis pain?

Intravenous treatment with tanezumab at 10 mg achieves the highest efficacy in terms of relieving pain in patients with osteoarthritis (OA), according to the results of a network meta-analysis.

What is the optimal tanezumab dose, administration route for osteoarthritis pain?